Literature DB >> 8895529

Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus.

J Kerr1, J A Leary, T Hurst, Y C Shih, T M Antalis, M Friedlander, E Crawford, S K Khoo, B Ward, G Chenevix-Trench.   

Abstract

The presence of a tumour suppressor gene on chromosome 7q is indicated by cytogenetic, loss of heterozygosity (LOH) and chromosome transfer studies. One candidate gene in this region is Plasminogen Activator Inhibitor-1 (PAI-1). The PAI-1 gene product is involved in proteolysis and may therefore influence tumour spread and invasion. We have analysed a series of 139 ovarian epithelial tumours at four loci in the region 7q21-q31 which includes the PAI-1 gene. The highest rates of loss were found in malignant tumours (FIGO stages I-IV) at markers D7S471 (38%, 20/52 informative cases) and D7S522 (34%, 15/44). No loss was seen in benign tumours and only one out of 27 (4%) informative LMP tumours demonstrated LOH. The smallest region of overlap (SRO) lies between D7S471 and PAI-1. We also identified a rearrangement in one tumour in the PAI-1 gene, suggesting that this may be the inactivated gene in this region. In addition LOH at the more distal marker, D7S522, which lies outside the SRO, shows significant association with stage (P=0.0343) and with LOH on chromosome 13 (P=0.0024). This is in contrast to all other markers examined. These data suggest the presence of two critical regions on 7q which may be important in subsets of epithelial ovarian tumours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895529

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

2.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Authors:  Kimberly J Bussey; Koei Chin; Samir Lababidi; Mark Reimers; William C Reinhold; Wen-Lin Kuo; Fuad Gwadry; Hosein Kouros-Mehr; Jane Fridlyand; Ajay Jain; Colin Collins; Satoshi Nishizuka; Giovanni Tonon; Anna Roschke; Kristen Gehlhaus; Ilan Kirsch; Dominic A Scudiero; Joe W Gray; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

Review 3.  Dmp1 and tumor suppression.

Authors:  K Inoue; A Mallakin; D P Frazier
Journal:  Oncogene       Date:  2007-01-22       Impact factor: 9.867

4.  Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade.

Authors:  F Galbiati; D Volonte; J A Engelman; G Watanabe; R Burk; R G Pestell; M P Lisanti
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

5.  Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation.

Authors:  Franco Capozza; Terence M Williams; William Schubert; Steve McClain; Boumediene Bouzahzah; Federica Sotgia; Michael P Lisanti
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

6.  Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.

Authors:  Hyangkyu Lee; David S Park; Babak Razani; Robert G Russell; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

7.  Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice.

Authors:  Terence M Williams; Michelle W-C Cheung; David S Park; Babak Razani; Alex W Cohen; William J Muller; Dolores Di Vizio; Neeru G Chopra; Richard G Pestell; Michael P Lisanti
Journal:  Mol Biol Cell       Date:  2003-03       Impact factor: 4.138

8.  Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.

Authors:  A Desai; J Xu; K Aysola; O Akinbobuyi; M White; V E Reddy; J Okoli; C Clark; E E Partridge; Ed Childs; D J Beech; M V Rice; Esp Reddy; V N Rao
Journal:  J Gynecol Res       Date:  2015-04-24

9.  Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.

Authors:  Ali Mallakin; Takayuki Sugiyama; Pankaj Taneja; Lauren A Matise; Donna P Frazier; Mayur Choudhary; Gregory A Hawkins; Ralph B D'Agostino; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

10.  Signal transduction involving the dmp1 transcription factor and its alteration in human cancer.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Robert D Kendig; Rachel L Morgan; Lauren A Matise; Sarah J Lagedrost; Kazushi Inoue
Journal:  Clin Med Oncol       Date:  2008-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.